Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

VCYT

+ Watchlist+ Portfolio

Veracyte, Inc.

Regulated industrySells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$24.23
52-Week Range
$21.91 – $60.91
Market Cap
$2.06B
P/E (TTM)
16.60
EPS (TTM)
1.54
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.44
PEG Ratio
—
Return on Equity
9.43%
Return on Assets
3.72%
Gross Margin
74.16%
Operating Margin
15.02%
Profit Margin
21.80%
Current Ratio
5.56
Debt/Equity
0.03
Total Debt
$40.74M
Free Cash Flow
$110.92M
Revenue Growth
15.10%
Earnings Growth
58.30%
Enterprise Value
$1.73B

Market Snapshot

About

Veracyte is a genomic diagnostics company that develops and commercializes molecular tests for cancer diagnosis. The company provides solutions for thyroid, lung, prostate, breast, and bladder cancers, helping physicians make treatment decisions. Its products include Afirma, Prosigna, Percepta, Envisia, and Decipher tests.